Anterix Inc. filings document the company’s 900 MHz private wireless broadband spectrum business, including material-event reports on spectrum license sale agreements, operating and financial results, Regulation FD updates, and capital-structure disclosures. The records include disclosures tied to broadband license sales, narrowband-to-broadband license exchanges, spectrum clearing costs, contracted proceeds, and the Demonstrated Intent key performance indicator.
The company’s SEC filings also cover governance matters, executive compensation and severance arrangements, shareholder voting matters, risk factors, and regulatory developments affecting broadband use of the 900 MHz band. Material agreements involving its wholly owned subsidiary, PDV Spectrum Holding Company, LLC, are documented through Form 8-K exhibits and related event disclosures.
Anterix Inc. (ATEX) reported that Chief Legal Officer & Corp Sec Gena L. Ashe exercised stock options for 6,833 shares of common stock at $34.96 per share on September 8, 2026. The exercise was handled on a cashless basis, with 2,769 shares withheld to cover the exercise price and income tax obligations, and the remaining shares largely sold in open-market transactions.
Anterix Inc. (ATEX) director Leslie B. Daniels reported selling 2,500 shares of common stock on September 10, 2026 in an open-market or private transaction at a weighted average price of $83.83 per share, with individual sale prices ranging from $84.25 to $83.55.
After this sale, Daniels directly held 43,477 shares, and also had indirect holdings of 2,000 shares through an IRA and 5,000 shares through a 401K.
Anterix Inc. (ATEX) has a notice of proposed sale of common stock filed under Rule 144 for the account of Heather Martin. The filing covers the potential sale of 8,064 shares of Anterix common stock, to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ.
The shares are described as restricted stock acquired from the issuer, and the filing lists an aggregate market value of $678,997.67 for the shares proposed to be sold. The notice is dated September 10, 2026.
Anterix Inc. (ATEX) received a notice under Rule 144 from officer Gena L. Ashe for a proposed sale of up to 4,357 shares of common stock through Morgan Stanley Smith Barney LLC. The shares consist of 293 restricted stock shares and 4,064 shares issuable upon stock option exercise. During the prior three months, Ashe sold 17,711 shares of Anterix common stock.
Anterix Inc. (ATEX) reported that Chief Legal Officer and Corporate Secretary Gena L. Ashe sold an aggregate of 4,357 shares of Anterix common stock on September 8, 2026, in two open-market or private transactions at $85.44 per share. No Rule 10b5-1 trading plan is reported for these sales.
Anterix Inc. (ATEX) director Leslie B. Daniels reported selling a total of 10,100 shares of Anterix common stock in open-market transactions on September 3–4, 2026. Reported prices included $87.15, $87.3103 and $86.50 per share, with some prices stated as weighted averages over intraday ranges.
After these transactions, Daniels was reported as holding 2,000 shares indirectly through an IRA and 5,000 shares indirectly through a 401(k) plan as of September 3, 2026. No Rule 10b5-1 trading plan was reported for these sales.
Anterix Inc. (ATEX) reported that Chief Reg & Comm Officer Christopher Guttman-McCabe exercised a stock option for 40,000 shares of common stock at an exercise price of $37.42 per share. The option was fully vested. The exercise was paid on a cashless basis, with the issuer withholding 16,561 shares to cover the exercise price and related income tax withholding and remittance obligations. On the same date, the reporting person sold an aggregate of 23,439 shares of common stock in open-market transactions at weighted average prices ranging from about $94.22 to $90.06 per share. The transactions were not reported as being made pursuant to a Rule 10b5-1 trading plan.
Anterix Inc. (ATEX) director and Executive Chairman Thomas R. Kuhn reported an option exercise and related share sales. On August 24, 2026, he exercised stock options for 10,000 shares of common stock at an exercise price of $33.62 per share, reducing that option position to 48,998 shares. He then sold an aggregate of 10,000 common shares in multiple open-market transactions on the same date at weighted-average prices between the high $80s and low $90s per share, plus an additional 1,654 shares sold on June 18, 2026 at $79.52 per share to cover tax withholding on RSU settlements. Earlier, on May 20, 2026, he received a grant of 2,791 restricted stock units, each representing one share of common stock, vesting in full on the earlier of May 20, 2027 or Anterix’s next annual stockholder meeting.
Anterix Inc. (ATEX) received a notice that officer Christopher Guttman-McCabe plans to sell 23,439 shares of common stock, with an aggregate market value of $2,164,837.76, on or about 08/25/2026 under Rule 144 following a stock option exercise. Common shares outstanding are reported as 19,609,786. In the prior three months, Guttman-McCabe reported sales of 122,852 shares of common stock for $10,042,745.59.
Anterix Inc. (ATEX) director Thomas Kuhn filed a Rule 144 notice indicating an intention to sell 10,000 shares of Anterix common stock through Morgan Stanley Smith Barney LLC on 08/24/2026, in connection with a stock option exercise. The proposed sale has an approximate aggregate market value of $888,527.00. Kuhn previously sold 1,654 shares of common stock on 06/18/2026 for proceeds of $131,526.08.